Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
The phase 1b trial characterised them: mostly ecchymosis (bruising, in 79% of those affected) and redness (32%), all mild, and, critically, not dose-dependent
Dosing is discussed at all because cagrilintide produced clinically meaningful weight reduction as a standalone agent in a phase 2 dose-finding trial, and because it is the amylin half of CagriSema the fixed-dose cagrilintide/semaglutide combination that Novo Nordisk filed with the FDA in December 2025
Expert Rev Endocrinol Metab 8(3):247259 Trujillo JM, Nuffer W (2014) Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes
It offers an alternative for those averse to injections but has different absorption rates and pharmacokinetic properties that may affect its efficacy and side effect profile
Meet our medical director, Dr
